Patent intelligence · US
US 10981860
Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof
Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof
Patent details — US 10981860
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 20, 2021
- Expiration
- Apr 15, 2041
- Applicant
- Medshine Discovery Inc.
- Claims
- 18
- CPC classes
- A61K, A61K31/445, A61K31/46, A61P
Quick answer
US 10981860 (Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof) is held by Medshine Discovery Inc.. Status: granted. Granted Apr 20, 2021. Expires Apr 15, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Medshine Discovery Inc.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K31/445, A61K31/46, A61P, A61P43/00
More from Medshine Discovery Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12427173
Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies
granted -
US 12428415
Matriptase 2 inhibitors and uses thereof
granted -
US 12421236
Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor
granted -
US 12420085
Synergistic therapies for inter vertebral disc degeneration
granted -
US 12421231
Azaindole derivatives and their use as ERK kinase inhibitors
granted -
US 12403069
Adapter for use in a planetary mixer
granted -
US 12398179
Nanomolar peptides and derivatives to differentially modulate ephrin receptors
granted -
US 12396924
Adapter for use in a planetary mixer
granted
Frequently asked questions
What is US patent 10981860?
US 10981860 (Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof) is held by Medshine Discovery Inc.. Status: granted. Granted Apr 20, 2021. Expires Apr 15, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10981860?
Medshine Discovery Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 706 pharmaceutical patents for this assignee.
When does US 10981860 expire?
Our index shows an expiration date of Apr 15, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.